Otsuka Canada Pharmaceutical

What Otsuka Canada Pharmaceutical does

Otsuka Canada Pharmaceutical Inc. (OCPI) is the Canadian commercial subsidiary of Otsuka Pharmaceutical Co., Ltd., a Japanese multinational healthcare company founded in 1921. Established in 2010 and headquartered in Saint-Laurent, Quebec, OCPI develops and commercializes a portfolio of ten prescription pharmaceutical brands across two therapeutic areas: neuroscience (schizophrenia, bipolar I disorder, major depressive disorder) and nephrology (ADPKD, ANCA-associated vasculitis, CKD-associated pruritus, hyperphosphatemia, hyperkalemia). Its core neuroscience franchise consists of multiple aripiprazole formulations — oral ABILIFY, monthly long-acting ABILIFY MAINTENA, and the recently listed once-every-two-month ABILIFY ASIMTUFII — co-commercialized with Lundbeck Canada, plus the atypical antipsychotic REXULTI (brexpiprazole). The nephrology franchise includes JINARC/SAMSCA (tolvaptan) for ADPKD, VELPHORO and VELTASSA for dialysis-related mineral disorders, KORSUVA (difelikefalin) for CKD-associated pruritus, and TAVNEOS (avacopan), a first-in-class oral C5a receptor inhibitor licensed from Vifor Fresenius Medical Care Renal Pharma. Underlying technology is rooted in proprietary Otsuka small-molecule chemistry and novel long-acting injectable formulation platforms rather than digital or computational systems.

OCPI generates revenue by selling branded prescription pharmaceuticals to authorized Canadian wholesalers/distributors and directly to hospital and retail pharmacy accounts under net-30 terms, with a $2,500 minimum order. Products are reimbursed through public drug plans after provincial formulary listings are secured — currently ABILIFY ASIMTUFII is reimbursed across seven provinces and the federal NIHB plan, covering over 90% of publicly-insured Canadians. The go-to-market model is a traditional enterprise pharmaceutical commercial approach targeting physicians, psychiatrists, nephrologists, and pharmacists, supported by a dedicated medical information portal for HCPs, product monographs, bilingual (English/French) corporate communications, and patient support programs for adherence. OCPI is part of the broader Otsuka group, which participates in a global 2021 collaboration with Sunovion and Sumitomo Dainippon Pharma for four additional neuropsychiatric compounds, providing future Canadian pipeline optionality.

Name

Otsuka Canada Pharmaceutical

Legal name

Otsuka Canada Pharmaceutical Inc.

Website

https://otsukacanada.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Short description

Otsuka Canada Pharmaceutical Inc. (OCPI) is the Canadian commercial subsidiary of Otsuka Pharmaceutical Co., Ltd., commercializing ten branded prescription pharmaceuticals in Canada across neuroscience (aripiprazole and brexpiprazole antipsychotics) and nephrology (ADPKD, dialysis-related disorders, and rare autoimmune kidney disease therapies) for physicians, psychiatrists, nephrologists, and patients.

Ownership category

akta.pro rank

Product category

Specialty Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Prescription pharmaceuticals
• Neuroscience therapeutics
• Nephrology treatments
• Long-acting injectables
• Rare disease therapies

Headquarters

HQ city

Saint Laurent

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations, Others

Revenue model

1. Pharmaceutical product sales: OCPI generates revenue by commercializing Otsuka-branded prescription pharmaceutical products in Canada, focusing on neuroscience and nephrology therapeutic areas. Products are sold to authorized distributors, hospital pharmacies, and retail pharmacies under standard payment terms (net 30).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Otsuka Canada Pharmaceutical Inc. (OCPI) develops, manufactures, and commercializes Otsuka-branded prescription pharmaceutical products in the Canadian market. Its portfolio is concentrated in two therapeutic areas: neuroscience (antipsychotics for schizophrenia, bipolar I disorder and major depressive disorder) and nephrology (treatments for autosomal dominant polycystic kidney disease, ANCA-associated vasculitis, CKD-associated pruritus, hyperphosphatemia and hyperkalemia). The company sells exclusively through authorized Canadian distributors, hospital and retail pharmacies, and holds provincial drug plan reimbursement listings.

Product overview

Otsuka Canada Pharmaceutical Inc. (OCPI) commercializes a portfolio of innovative prescription pharmaceutical products in Canada, with a strategic focus on two core therapeutic areas: neuroscience (psychiatry/neuropsychiatry) and nephrology/kidney disease. The neuroscience portfolio includes multiple formulations of aripiprazole (ABILIFY® tablet, ABILIFY MAINTENA® monthly injectable, ABILIFY ASIMTUFII® two-month injectable) and brexpiprazole (REXULTI®), all for psychiatric conditions, with some co-commercialized through partnerships with Lundbeck Canada Inc. The nephrology portfolio encompasses treatments for polycystic kidney disease (JINARC®, SAMSCA®), hyperphosphatemia in dialysis patients (VELPHORO®), hyperkalemia (VELTASSA®), and CKD-associated pruritus (KORSUVA®), as well as TAVNEOS® for ANCA-associated vasculitis, a rare autoimmune kidney disease. OCPI operates as the Canadian subsidiary of Otsuka Pharmaceutical Co., Ltd., headquartered in St-Laurent, Quebec.

Differentiator

Problem solved

Functional benefit

Products and services

• ABILIFY (aripiprazole)

Quantifiable outcome

• ABILIFY ASIMTUFII achieved public reimbursement coverage across 7 Canadian provinces and federal drug plans, reaching over 90% of Canadians covered by public drug plans.
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and flagship.

• Lundbeck Canada Inc.coreStrategic or Co-development Partner · 4 March 2026Otsuka Pharmaceutical Canada Inc. and Lundbeck Canada Inc. co-commercialize ABILIFY ASIMTUFII® (aripiprazole), a once-every-two-months long-acting injectable for schizophrenia and bipolar I disorder maintenance therapy. Together they secured public reimbursement coverage across seven Canadian provinces and federal drug plans.
• Sunovion Pharmaceuticals Inc.flagshipStrategic or Co-development Partner · 30 September 2021Otsuka Pharmaceutical Co., Ltd. entered a global license agreement with Sunovion and its parent Sumitomo Dainippon Pharma for the joint development and commercialization of four neuropsychiatric compounds: ulotaront (SEP-363856), amisulpride enantiomer mixture (SEP-4199), SEP-378614, and SEP-380135. Sunovion and Otsuka co-direct global R&D and commercialization activities, sharing profits and clinical development costs.
• Sumitomo Dainippon Pharma Co., Ltd.flagshipStrategic or Co-development Partner · 30 September 2021Parent company of Sunovion Pharmaceuticals Inc. Sunovion and Otsuka concluded a global development and commercialization collaboration involving four neuropsychiatric compounds. The agreement includes an upfront payment of $270 million USD to Sunovion, with potential development milestone payments up to $620 million USD and sales-based payments.
• Vifor Fresenius Medical Care Renal PharmacoreChannel Partner/ Reseller/ Distributor · 1 April 2021In April 2021, Otsuka Canada obtained from Vifor Fresenius Medical Care Renal Pharma the exclusive rights for the promotion and distribution of Tavneos (avacopan) in Canada. Tavneos is a first-in-class oral C5a receptor inhibitor for ANCA-associated vasculitis.

Scale indicators2 records

Recent moves8 records

Expansion highlights5 records

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Customer concentration

• LinkedInlinkedin.com/company/otsuka-canada-pharmaceutical-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Otsuka Canada Pharmaceutical